New Frontiers in the Treatment and
Management of Heart Failure: A Closer Look at the Role of New
A continuing medical education
activity provided by NAMCP and AAMCN
New Frontiers in the Treatment and Management of Heart Failure: A
Look at the Role of New Therapies is a two-part webinar series
This is Part 1 of the series focusing on New Frontiers in the
Treatment and Management of
Heart Failure: A Closer Look at the Role of New Therapies
This activity is an archive from the webinar held May 12, 2021.
This activity is valid from June 1, 2021 to June 1, 2023
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from
Merck Sharp & Dohme Corp.
Heart failure (HF) is a common condition that affects approximately
5.7 million people in the United States, and the prognosis for
patients with heart failure has traditionally been poor. Projections
show that by 2030, the prevalence of heart failure will increase 46
percent from recent estimates. HF is the reason for more than 1
million hospitalizations per year and an estimated $31 billion in
costs in the U.S. each year. Fortunately for patients with HF, new
and emerging therapeutic options have improved both clinical and
economic outcomes for these patients and the system.
Upon completion of this
activity, participants will be able to:
Examine the unmet clinical needs in
heart failure and the impact of inadequately treated disease on
physical and mental health, quality of life, costs and work
Review the latest clinical evidence
regarding the safety and efficacy of sGC modulators for treating
patients with HF with reduced ejection fraction (HFrEF)
Assess the role of sGC modulators
and how they fit into current treatment paradigms for the
management of HF
Summarize evidence of HF
interventions shown to reduce hospitalizations, morbidity, and
||Javed Butler, MD, MBA,
Patrick A. Lehan Chair in Cardiovascular Research
Professor of Medicine and Physiology
University of Mississippi
has served as a consultant for Abbott, Adrenomed, Amgen,
Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol
Meyers Squib, CVRx, G3 Pharmaceutical, Impulse Dynamics,
Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck,
Novartis, NovoNordsik, and Vifor. Dr. Butler has served
as a speaker for Novartis, AstraZeneca, Boehringer
Ingelheim/Lilly, and Janssen.
MD has no financial relationships with ineligible
companies to disclose.
Jeremy Williams has no financial relationships with
ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial
relationships with ineligible companies to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue